Global Anti-EpilepticDrugs Market, by Generation (First Generation, Second Generation, and ThirdGeneration), by Route of Administration (Oral and Intravenous), by DistributionChannel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), andby Region (North America, Latin America, Europe, Asia Pacific, Middle East, andAfrica) is estimated to be valued at US$ 7,155.6 million in 2019 and is estimated to exhibit a CAGR of 6.6%overthe forecast period (2019-2027), as highlighted in a new report published byCoherent Market Insights.
The number of availableanti-epilepsy drugs has doubled over the past several decades as the benefitsof anti-epilepsy medicines are higher than the possible side-effects from themedicine. Moreover, the U.S. FDA has approved 28 drugs for the treatment ofepilepsy and many generic versions of anti-epileptic drugs have been launchedby manufacturers.
The U.S. FDA has only approvedanticonvulsant medications for seizure disorders in children. Moreover, thecurrently available newer anti-seizure drugs have simple pharmacokinetics andmore limited effects on liver metabolism, thus driving growth of theanti-epileptic drugs market for pediatrics.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1701
The increasing improvements inefficacy of medications of treating epilepsy is expected to fuel growth of theanti-epileptic drugs market over the forecast period. For instance, newer drugshave exhibited better efficacy, owing to better pharmacokinetic profiles andfewer drug interactions than the classic first-generation drugs. For instance,the third-generation drugs developed by UCB’s Keppra (levetiracetam) andGlaxoSmithKline’s (GSK’s) Lamictal (lamotrigine) transitioned rapidly to the‘Blockbuster’ status and have replaced the older gold standards in most of themarkets as first-line treatments. According to the Epilepsy Foundation reportof 2013, the newer third-generation AEDs have provided complete control overseizures to over half of the patients with epilepsy and reduced the number ofseizures in another 20-30% of patients, thereby proving the success rate of thenewer AEDs.
Browse 35 Market Data Tables and30 Figures spread through 201 Pages and in-depth TOC on "GlobalAnti-epileptic Drugs Market, by Generation (First Generation, SecondGeneration, and Third Generation), by Route of Administration (Oral andIntravenous), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies,and Online Pharmacies), and by Region (North America, Latin America, Europe,Asia Pacific, Middle East, and Africa) - Global Forecast to 2027"
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/antiepileptic-drugs-market-1701
Key Takeaways of the GlobalAnti-epileptic Drugs Market:
The global anti-epileptic drugmarket expected to exhibit a CAGR of 6.6% over the forecast period (2019-2027),owing to emergence of novel efficacious anti-epileptic drugs
Among generation, thirdgeneration segment is expected to account for major revenue share by 2027,owing to rising demand for third generation anti-epileptic drugs, which israpidly outpacing the first generation and second generation anti-epilepticdrugs, mostly for the treatment of children and adolescents.
Major players operating in theglobal anti-epileptic drug market include Novartis AG, GlaxoSmithKline Plc, Johnson & JohnsonService, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A.,Sumitomo Dainippon Pharma Co., Ltd., Mylan N.V., Bausch Health Companies Inc.,and UCB S.A.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1701
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
